Phaseline

Companies › Zymeworks BC

Zymeworks BC: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZW191–Phase 1Advanced Solid TumorsDec 2026
ZW251
anti-GPC3 antibody-drug conjugate
GPC3Phase 1Hepatocellular CarcinomaSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06555744ZW191Phase 1Advanced Solid TumorsOncologyDec 2026
NCT07164313ZW251Phase 1Hepatocellular CarcinomaOncologySep 2027

From the company's SEC filings

Cash of $100m on 2026-09-30; operating cash outflow about $136m a year; runway about 9 months at that burn, to Jun 2027

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Targets

GPC3 (1)

Companies with the same targets

AstraZeneca Keymed Biosciences Co.Ltd Newish Technology (Beijing) Aptamer Sciences Shanghai Chia Tai Tianqing Pharmaceutical Technology Development RayzeBio SOTIO Biotech Bayer BeOne Medicines

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.